[74]
Apotex alleges that claim 4 addresses the specific compound levofloxacin which does not include within its scope its hydrated forms, including the hemihydrate form, or its salt forms. In support of their construction, Apotex relies on Justice Mosley's decision in
Novopharm
, above, wherein claim 4 was not construed as including within its scope the compound levofloxacin hemihydrate. (NOA, p. 3495 AR.)